Patents by Inventor Jacqueline Wyatt

Jacqueline Wyatt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antisense modulation of MP-1 expression
    Patent number: 6306606
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MP-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MP-1. Methods of using these compounds for modulation of MP-1 expression and for treatment of diseases associated with expression of MP-1 are provided.
    Type: Grant
    Filed: November 22, 2000
    Date of Patent: October 23, 2001
    Assignees: ISIS Pharmaceuticals, Inc., University of Virginia
    Inventors: Michael J. Weber, Jacqueline Wyatt, Lex M. Cowsert
  • Antisense inhibition of C/EBP alpha expression
    Patent number: 6306655
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of C/EBP alpha. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding C/EBP alpha. Methods of using these compounds for modulation of C/EBP alpha expression and for treatment of diseases associated with expression of C/EBP alpha are provided.
    Type: Grant
    Filed: June 13, 2000
    Date of Patent: October 23, 2001
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Madeline M. Butler, Jacqueline Wyatt
  • Antisense inhibition of MEKK2 expression
    Patent number: 6287860
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MEKK2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEKK2. Methods of using these compounds for modulation of MEKK2 expression and for treatment of diseases associated with expression of MEKK2 are provided.
    Type: Grant
    Filed: January 20, 2000
    Date of Patent: September 11, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, William Gaarde, Donna T. Ward, Susan M. Freier, Jacqueline Wyatt
  • Antisense inhibition of C/EBP beta expression
    Patent number: 6271030
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of C/EBP beta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding C/EBP beta. Methods of using these compounds for modulation of C/EBP beta expression and for treatment of diseases associated with expression of C/EBP beta are provided.
    Type: Grant
    Filed: June 14, 2000
    Date of Patent: August 7, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Madeline M. Butler, Jacqueline Wyatt
  • Antisense modulation of macrophage migration inhibitory factor expression
    Patent number: 6268151
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Macrophage migration inhibitory factor. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Macrophage migration inhibitory factor. Methods of using these compounds for modulation of Macrophage migration inhibitory factor expression and for treatment of diseases associated with expression of Macrophage migration inhibitory factor are provided.
    Type: Grant
    Filed: January 20, 2000
    Date of Patent: July 31, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Susan Murray, Lex M. Cowsert, Jacqueline Wyatt
  • Antisense modulation of cot oncogene expression
    Patent number: 6265216
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of cot oncogene. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding cot oncogene. Methods of using these compounds for modulation of cot oncogene expression and for treatment of diseases associated with expression of cot oncogene are provided.
    Type: Grant
    Filed: January 20, 2000
    Date of Patent: July 24, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Jacqueline Wyatt
  • Antisense modulation of PTP1B expression
    Patent number: 6261840
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided.
    Type: Grant
    Filed: January 18, 2000
    Date of Patent: July 17, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Lex M. Cowsert, Jacqueline Wyatt
  • Antisense modulation of ARA70 expression
    Patent number: 6255110
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of ARA70. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding ARA70. Methods of using these compounds for modulation of ARA70 expression and for treatment of diseases associated with expression of ARA70 are provided.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: July 3, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Lex M. Cowsert, Jacqueline Wyatt
  • Antisense modulation of pepck-cytosolic expression
    Patent number: 6187545
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PEPCK-cytosolic. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PEPCK-cytosolic. Methods of using these compounds for modulation of PEPCK-cytosolic expression and for treatment of diseases associated with expression of PEPCK-cytosolic are provided.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: February 13, 2001
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Robert McKay, Madeline M. Butler, Jacqueline Wyatt, Lex M. Cowsert
  • Antisense inhibition of E2F transcription factor 3 expression
    Patent number: 6165791
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of E2F transcription factor 3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding E2F transcription factor 3. Methods of using these compounds for modulation of E2F transcription factor 3 expression and for treatment of diseases associated with expression of E2F transcription factor 3 are provided.
    Type: Grant
    Filed: February 24, 2000
    Date of Patent: December 26, 2000
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Ian Popoff, Jacqueline Wyatt
  • Antisense inhibition of methionine aminopeptidase 2 expression
    Patent number: 6136604
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of methionine aminopeptidase 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding methionine aminopeptidase 2. Methods of using these compounds for modulation of methionine aminopeptidase 2 expression and for treatment of diseases associated with expression of methionine aminopeptidase 2 are provided.
    Type: Grant
    Filed: October 27, 1999
    Date of Patent: October 24, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Jacqueline Wyatt
  • Methods for synthetic unrandomization of oligomer fragments
    Patent number: 5698391
    Abstract: Methods useful for the determination of oligomers which have specific activity for a target molecule from a pool of primarily randomly assembled oligomers are provided. The disclosed methods involve repeated syntheses of increasingly simplified sets of oligomers coupled with selection procedures for determining oligomers having the highest activity. Freedom from the use of enzymes allows the application of these methods to any molecules which can be oligomerized in a controlled fashion.
    Type: Grant
    Filed: December 16, 1994
    Date of Patent: December 16, 1997
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, David J. Ecker, Jacqueline Wyatt, Thomas W. Bruice, Kevin Anderson, Ronnie Hanecak, Timothy Vickers, Peter Davis, Susan M. Freier, Yogesh S. Sanghvi, Vickie Brown-Driver
  • Synthetic unrandomization of oligomer fragments
    Patent number: 5672472
    Abstract: Methods useful for the determination of oligomers which have specific activity for a target molecule from a pool of primarily randomly assembled subunits are provided. The disclosed methods involve repeated syntheses of increasingly simplified sets of oligomers coupled with selection procedures for determining oligomers having the highest activity. Freedom from the use of enzymes allows the application of these methods to any molecules which can be oligomerized in a controlled fashion.
    Type: Grant
    Filed: February 22, 1994
    Date of Patent: September 30, 1997
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: David J. Ecker, Jacqueline Wyatt, Thomas W. Bruice, Kevin Anderson, Ronnie C. Hanecak, Timothy Vickers, Peter Davis